AstraZeneca divests rights to Arimidex and Casodex in Europe and certain additional countries
20 December 2019 07:00 GMT AstraZeneca divests rights to Arimidex and Casodex in Europe and certain additional countries Sale to Juvisé Pharmaceuticals supports AstraZeneca's strategy of focusing on pipeline of new medicines AstraZeneca today announced that it has agreed to sell the commercial rights to Arimidex (anastrozole) and Casodex (bicalutamide) in a number of European, African and other countries[1] to Juvisé Pharmaceuticals. The medicines, used primarily to treat breast and prostate cancers, have lost their compound patent protection in these